Quality of life in sarcoidosis

Catharina C Moor; Ogugua Ndili Obi; Vivienne Kahlmann; Katharina Buschulte; Marlies S Wijsenbeek

doi:10.1016/j.jaut.2023.103123

Quality of life in sarcoidosis

J Autoimmun. 2023 Oct 7:103123. doi: 10.1016/j.jaut.2023.103123. Online ahead of print.

Authors

Catharina C Moor¹, Ogugua Ndili Obi², Vivienne Kahlmann¹, Katharina Buschulte³, Marlies S Wijsenbeek⁴

Affiliations

¹ Department of Respiratory Medicine, Centre of Excellence for Interstitial Lung Diseases and Sarcoidosis, Erasmus Medical Center, Rotterdam, the Netherlands.
² Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
³ Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany.
⁴ Department of Respiratory Medicine, Centre of Excellence for Interstitial Lung Diseases and Sarcoidosis, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: m.wijsenbeek-lourens@erasmusmc.nl.

PMID: 37813805
DOI: 10.1016/j.jaut.2023.103123

Abstract

Having sarcoidosis often has a major impact on quality of life of patients and their families. Improving quality of life is prioritized as most important treatment aim by many patients with sarcoidosis, but current evidence and treatment options are limited. In this narrative review, we describe the impact of sarcoidosis on various aspects of daily life, evaluate determinants of health-related quality of life (HRQoL), and provide an overview of the different patient-reported outcome measures to assess HRQoL in sarcoidosis. Moreover, we review the current evidence for pharmacological and non-pharmacological interventions to improve quality of life for people with sarcoidosis.

Keywords: Health-related quality of life; Non-pharmacological treatment; Sarcoidosis; Symptom palliation.